Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Initiation of Phase 1/2 Trial of BEAM-302 in AATD Expected in First Half of 2024

Excerpt from the Press Release:

CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the clearance of its clinical trial authorisation (CTA) application by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency for BEAM-302, an in vivo base editor, as a potential treatment for patients with alpha-1 antitrypsin deficiency (AATD).

“The clearance of our first CTA is an important step in the advancement of our global Phase 1/2 study of BEAM-302, a potentially best-in-class, liver-targeting in vivo base editor designed to correct the PiZ mutation, which is the most common gene variant associated with severe AATD,” said Giuseppe Ciaramella, Ph.D., president of Beam. “AATD is an inherited genetic condition that can cause serious lung and liver disease, which can lead to significant debility and reduced life expectancy for patients. Preclinical data demonstrated the ability of BEAM-302 to significantly increase levels of corrected and functional alpha-1 antitrypsin (AAT) and reduce the mutant PiZ AAT protein in in vivo rodent disease models at clinically relevant doses. These findings support the potential of BEAM-302 to efficiently correct the disease-causal PiZ mutation after a single dose and potentially address both the liver and lung disease associated with AATD.”

The Phase 1/2 clinical trial is an open-label, dose-escalation study that will evaluate the safety, pharmacodynamics, pharmacokinetics and efficacy of BEAM-302 initially in patients with AATD-associated lung disease.

Click the button below to read the entire Press Release:

Continue Reading The Press Release